World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
37231
World Ranking
14864
National Ranking
208

Albert Oriol publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Albert Oriol sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 728 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Albert Oriol D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Albert Oriol sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Albert Oriol is affiliated with the Autonomous University of Barcelona in Spain. Their research primarily focuses on the fields of medicine and biochemistry, genetics, and molecular biology. Within these broader disciplines, their work concentrates notably on hematology, oncology, molecular biology, genetics, and radiology, nuclear medicine and imaging.

The scientist's main topics of research include multiple myeloma research and treatments, protein degradation and inhibitors, peptidase inhibition and analysis, CAR-T cell therapy research, cancer treatment and pharmacology, monoclonal and polyclonal antibodies research, and chronic lymphocytic leukemia research.

Frequent co-authors collaborating with Albert Oriol are María-Victoria Mateos, Jesús F. San Miguel, Paula Rodríguez-Otero, Joaquin Martínez-López, and Laura Rosiñol.

Albert Oriol has published extensively in several scientific venues. The most frequent journals include Clinical Lymphoma Myeloma & Leukemia, Blood, Journal of Clinical Oncology, HemaSphere, and Blood Cancer Journal.

Several recent papers include:

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma, 2021, New England Journal of Medicine
  • Teclistamab in Relapsed or Refractory Multiple Myeloma, 2022, New England Journal of Medicine
  • Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma, 2023, New England Journal of Medicine
  • Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma, 2022, New England Journal of Medicine
  • Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial, 2021, The Lancet

Best Publications

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

    Hagop M. Kantarjian;Xavier G. Thomas;Anna Dmoszynska;Agnieszka Wierzbowska

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial;Brendan M Weiss;Saad Z Usmani;Seema Singhal

  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

    Lotfi Benboubker;Meletios Athanasios Dimopoulos;Angela Dispenzieri;John Catalano

  • Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

    María-Victoria Mateos;Miguel-Teodoro Hernández;Pilar Giraldo;Javier de la Rubia

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

    Laura Rosiñol;Albert Oriol;Ana Isabel Teruel;Dolores Hernández

  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    María-Victoria Mateos;María-Victoria Mateos;José-M. Hernández;José-M. Hernández;Miguel-T. Hernández;Miguel-T. Hernández;Norma-C. Gutiérrez;Norma-C. Gutiérrez

  • Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González

  • Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

    Meletios A. Dimopoulos;Hartmut Goldschmidt;Ruben Niesvizky;Douglas Joshua

  • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales

  • Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

    Josep-María Ribera;Albert Oriol;Miguel-Angel Sanz;Mar Tormo

  • Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

    Albert Oriol;Susana Vives;Jesús-María Hernández-Rivas;Mar Tormo

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

    Josep-Maria Ribera;Albert Oriol;Mireia Morgades;Pau Montesinos

  • Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

    Juan-Jose Lahuerta;Bruno Paiva;Maria-Belen Vidriales;Lourdes Cordón

  • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

Frequent Co-Authors

Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Joan Bladé
Joan Bladé University of Barcelona
Juan José Lahuerta
Juan José Lahuerta Complutense University of Madrid
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra
Josep-Maria Ribera
Josep-Maria Ribera Autonomous University of Barcelona
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Ramón García-Sanz
Ramón García-Sanz University of Salamanca
Philippe Moreau
Philippe Moreau University of Nantes
Michele Cavo
Michele Cavo University of Bologna
Paul G. Richardson
Paul G. Richardson Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but are still exploring your options, there are several online degree paths and career pathways beyond traditional medical school. Many students consider alternative programs such as direct msn programs online. These are ideal for non-nursing graduates seeking a direct route to a Master’s in Nursing, making it possible to join the healthcare field without a prior nursing degree.

Entry-level roles in nursing are also in high demand. For those with little or no prior experience, accredited online adn programs for non nurses offer a convenient pathway toward becoming a Registered Nurse (RN). Additionally, not all programs require rigorous entrance exams. Prospects can explore whether do you have to take a teas test for lpn is mandatory for their desired program.

For those interested in the administrative side of healthcare, there are reputable medical billing and coding online schools that can lead to in-demand career opportunities working behind the scenes. Each of these flexible online programs offers a unique route to a rewarding healthcare career, with varying requirements and outcomes depending on your interests and past education.

Best Scientists Citing Albert Oriol

Trending Scientists

Recently Published Articles